SEC v. BRISTOL-MYERS SQUIBB COMPANY, No. 3:18-cv-01530 (July 16, 2018)
raw: suspension of trading in the securities of Kelvin Medical, Inc. (“KVMD”), commencing at 9:30
suspension of trading in the securities of Kelvin Medical, Inc. (“KVMD”), commencing at 9:30, No. 3:18-cv-01530 (July 16, 2018)
The U.S. Securities and Exchange Commission (SEC) temporarily suspended trading in Kelvin Medical, Inc. (KVMD) securities due to concerns over inaccurate information and potentially manipulative transactions, with no specific fraud charges or monetary penalties filed.
The SEC temporarily suspended trading in KVMD securities from March 20 to April 3, 2018, due to concerns over inaccurate or inadequate public information and potentially manipulative trading activity. No specific dollar amounts or monetary penalties were mentioned in the action. The SEC warned brokers, dealers, and investors to exercise caution and comply with Rule 15c2-11 before resuming quotations in KVMD shares post-suspension.
The U.S. Securities and Exchange Commission (SEC) temporarily suspended trading in Kelvin Medical, Inc. (KVMD) securities from March 20 to April 3, 2018, due to concerns over inaccurate or inadequate public information and potentially manipulative trading activity in its common stock. The suspension was a precautionary measure under Section 12(k) of the Securities Exchange Act of 1934. No specific fraud charges or monetary penalties were filed in this action. The SEC warned brokers, dealers, and investors to exercise caution and comply with Rule 15c2-11 before resuming quotations in KVMD shares post-suspension. The order did not allege criminal conduct but emphasized the need for transparency and regulatory compliance. Investors and market participants were urged to contact the SEC with any relevant information regarding potential misconduct. The SEC also invited tips related to the matter through its whistleblower contact.
Extracted insights
- person enforcement action
- company kvmd’s securities
- company temporary suspension of trading in the securities of kelvin medical, inc.
- U.S. Securities and Exchange Commission announced temporary suspension of trading in the securities of Kelvin Medical, Inc.
- Commission suspended trading KVMD’s securities
- Commission entered order pursuant to Section 12(k) of the Securities Exchange Act of 1934
- Commission cautions brokers, dealers, shareholders, and prospective purchasers
- Commission consider enforcement action
- person contact Judith Weinstock, Esq.
- U.S. Securities and Exchange Commission suspended trading securities of Kelvin Medical, Inc. (KVMD) from March 20, 2018, 9:30 a.m. EDT to April 3, 2018, 11:59 p.m. EDT
- U.S. Securities and Exchange Commission suspended trading KVMD’s common stock due to concerns about inaccurate or inadequate information and potentially manipulative transactions
- U.S. Securities and Exchange Commission cautioned brokers, dealers, shareholders, and prospective purchasers to consider all available information before trading KVMD securities
- U.S. Securities and Exchange Commission enforced Rule 15c2-11 requiring compliance before quoting KVMD securities after suspension termination
- U.S. Securities and Exchange Commission will consider prompt enforcement action against brokers or dealers violating Rule 15c2-11
- U.S. Securities and Exchange Commission requested any person with related information to contact Judith Weinstock, Esq. at [email protected] or (212) 336-9078
- U.S. Securities and Exchange Commission announced temporary suspension of trading in Kelvin Medical, Inc. securities
- U.S. Securities and Exchange Commission suspended trading in KVMD's securities
- The Commission cautions brokers, dealers, shareholders, and prospective purchasers
- broker or dealer should contact staff of the Securities and Exchange Commission
- broker, dealer, or other person should contact Judith Weinstock, Esq.
- The Commission will consider the need for prompt enforcement action
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SECURITIES EXCHANGE ACT OF 1934 Release No. 82903 / March 19, 2018 The U.S. Securities and Exchange Commission (“Commission”) announced the temporary suspension of trading in the securities of Kelvin Medical, Inc. (“KVMD”), commencing at 9:30 a.m. EDT on March 20, 2018 and terminating at 11:59 p.m. EDT on April 3, 2018. The Commission temporarily suspended trading in KVMD’s securities due to concerns about the accuracy and adequacy of information in the marketplace and potentially manipulative transactions in KVMD’s common stock. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act). The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by KVMD. Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspensions, no quotation may be entered relating to KVMD’s securities unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to KVMD’s securities until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5720. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action. If any broker, dealer, or other person has any information which may relate to this matter, they should immediately contact Judith Weinstock, Esq., at [email protected] or (212) 336-9078.
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SECURITIES EXCHANGE ACT OF 1934 Release No. 82903 / March 19, 2018 The U.S. Securities and Exchange Commission (“Commission”) announced the temporary suspension of trading in the securities of Kelvin Medical, Inc. (“KVMD”), commencing at 9:30 a.m. EDT on March 20, 2018 and terminating at 11:59 p.m. EDT on April 3, 2018. The Commission temporarily suspended trading in KVMD’s securities due to concerns about the accuracy and adequacy of information in the marketplace and potentially manipulative transactions in KVMD’s common stock. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act). The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by KVMD. Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspensions, no quotation may be entered relating to KVMD’s securities unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to KVMD’s securities until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5720. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action. If any broker, dealer, or other person has any information which may relate to this matter, they should immediately contact Judith Weinstock, Esq., at [email protected] or (212) 336-9078.